Developing new biopharmaceutical products for infectious diseases
Official title: Preclinical Services for Biopharmaceutical Product Development
Funded at Latham Biopharm Group, INC. · NIH-10934794 · Data updated 2026-11-12
This study is working on improving new treatments, like antibodies and special proteins, to help fight infections, so patients can eventually benefit from better therapies.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Latham Biopharm Group, INC. NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project start | September 8, 2023 |
| Project end | September 7, 2030 |
| Funding year | 2023 |
| Award (this year) | $1,000 |
| NIH project number | 75N93023D00014-0-759302300001-2 |
| Project ID | NIH-10934794 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation or benefit from this research are individuals affected by infectious diseases who may be treated with novel biopharmaceutical products.
✕Less likely to help
Patients with non-infectious diseases or those not responding to biopharmaceutical treatments may not receive benefits from this research.
What this research studies
This research focuses on providing essential services for the preclinical development of biopharmaceutical products, including monoclonal antibodies, recombinant proteins, and nucleic acid-based vectors like small interfering RNA. The program aims to facilitate the planning, evaluation, and characterization of these products, ensuring they are effectively developed for use against infectious diseases. Patients may benefit from advancements in treatments that arise from this preclinical work, as it supports the translation of innovative therapies into clinical settings.
Why it matters
Potential benefit: If successful, this research could lead to the development of new and effective treatments for infectious diseases.
How similar studies have gone: Other research in biopharmaceutical development has shown success in translating preclinical findings into effective treatments, indicating a promising potential for this approach.
Where this research is happening
-
Latham Biopharm Group, INC.
Cambridge, United States Active
Related research
Other NIH-funded projects on the same topics.
-
Developing new treatments to combat bacterial resistance using biopharmaceuticals
This study is working on new treatments to help fight infections caused by bacteria that don't respond to regular medicines, using cutting-edge technology to create helpful products like antibodies and proteins, and it's designed for anyone interested in better options for treating tough infections.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.